146 related articles for article (PubMed ID: 20554312)
21. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
Brunner S; Kim JO; Methe H
Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
[TBL] [Abstract][Full Text] [Related]
22. Host single nucleotide polymorphisms of MMP-9 -1562/TIMP-1 372 have gender differences in the risk of gastric intestinal metaplasia after Helicobacter pylori infection.
Hung KH; Hung HW; Yang HB; Lu CC; Wu JJ; Sheu BS
Helicobacter; 2009 Dec; 14(6):580-7. PubMed ID: 19889076
[TBL] [Abstract][Full Text] [Related]
23. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
[TBL] [Abstract][Full Text] [Related]
24. A novel tissue inhibitor of metalloproteinase-1 (TIMP-1) polymorphism associated with asthma in Australian women.
Lose F; Thompson PJ; Duffy D; Stewart GA; Kedda MA
Thorax; 2005 Aug; 60(8):623-8. PubMed ID: 16061701
[TBL] [Abstract][Full Text] [Related]
25. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension.
Tan J; Hua Q; Xing X; Wen J; Liu R; Yang Z
Hypertens Res; 2007 Oct; 30(10):959-63. PubMed ID: 18049028
[TBL] [Abstract][Full Text] [Related]
26. Matrix metalloproteinase (MMP)-2 genetic variants modify the circulating MMP-2 levels in end-stage kidney disease.
Marson BP; Lacchini R; Belo V; Dickel S; da Costa BP; Poli de Figueiredo CE; Tanus-Santos JE
Am J Nephrol; 2012; 35(3):209-15. PubMed ID: 22302011
[TBL] [Abstract][Full Text] [Related]
27. Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension.
Tayebjee MH; Karalis I; Nadar SK; Beevers DG; MacFadyen RJ; Lip GY
Am J Hypertens; 2005 Mar; 18(3):325-9. PubMed ID: 15797648
[TBL] [Abstract][Full Text] [Related]
28. Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans.
Nakamura T; Matsuda T; Suzuki Y; Ueda Y; Koide H
ASAIO J; 2003; 49(4):430-4. PubMed ID: 12918586
[TBL] [Abstract][Full Text] [Related]
29. Matrix metalloproteinase-9 polymorphisms affect plasma MMP-9 levels and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy.
Palei AC; Sandrim VC; Amaral LM; Machado JS; Cavalli RC; Lacchini R; Duarte G; Tanus-Santos JE
Pharmacogenomics J; 2012 Dec; 12(6):489-98. PubMed ID: 21769110
[TBL] [Abstract][Full Text] [Related]
30. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function.
Kosmala W; Plaksej R; Przewlocka-Kosmala M; Kuliczkowska-Plaksej J; Bednarek-Tupikowska G; Mazurek W
Int J Obes (Lond); 2008 May; 32(5):763-71. PubMed ID: 18197181
[TBL] [Abstract][Full Text] [Related]
31. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
[TBL] [Abstract][Full Text] [Related]
32. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
[TBL] [Abstract][Full Text] [Related]
33. Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes.
Lee SW; Song KE; Shin DS; Ahn SM; Ha ES; Kim DJ; Nam MS; Lee KW
Diabetes Res Clin Pract; 2005 Aug; 69(2):175-9. PubMed ID: 16005367
[TBL] [Abstract][Full Text] [Related]
34. Serum levels of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 in subacute sclerosing panencephalitis.
Ichiyama T; Siba P; Suarkia D; Takasu T; Miki K; Kira R; Kusuhara K; Hara T; Toyama J; Furukawa S
J Neurol Sci; 2007 Jan; 252(1):45-8. PubMed ID: 17118404
[TBL] [Abstract][Full Text] [Related]
35. Association between matrix metalloproteinase (MMP)-2 polymorphisms and MMP-2 levels in hypertensive disorders of pregnancy.
Palei AC; Sandrim VC; Amaral LM; Machado JS; Cavalli RC; Duarte G; Tanus-Santos JE
Exp Mol Pathol; 2012 Apr; 92(2):217-21. PubMed ID: 22327101
[TBL] [Abstract][Full Text] [Related]
36. Matrix metalloproteinase-9 promoter polymorphisms in Korean patients with systemic lupus erythematosus.
Lee YJ; Woo M; Nam JH; Baek J; Im CH; Lee EY; Lee EB; Park KS; Song YW
Hum Immunol; 2008 Jun; 69(6):374-9. PubMed ID: 18571010
[TBL] [Abstract][Full Text] [Related]
37. [The role of matrix metalloproteinases-9 and tissue inhibitor of metalloproteinaes-1 in chronic obstructive pulmonary disease].
Xu XM; Sun TY; Lin JB; Zhang HS
Zhonghua Yi Xue Za Zhi; 2003 Jul; 83(13):1138-41. PubMed ID: 12921631
[TBL] [Abstract][Full Text] [Related]
38. Effect of angiotensin II receptor blocker on glucose-induced mRNA expressions of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in rat mesangial cells.
Ding HL; Guo Y; Xu MT; Li HY; Fu ZZ
Chin Med J (Engl); 2007 Nov; 120(21):1886-9. PubMed ID: 18067760
[TBL] [Abstract][Full Text] [Related]
39. Genetic variation, gene-expression and circulating levels of matrix metalloproteinase-9 in patients with stable coronary artery disease.
Opstad TB; Pettersen AA; Weiss TW; Akra S; Øvstebø R; Arnesen H; Seljeflot I
Clin Chim Acta; 2012 Jan; 413(1-2):113-20. PubMed ID: 21963461
[TBL] [Abstract][Full Text] [Related]
40. [Alterations of metalloproteinases and their inhibitors concentrations in peripheral blood in children with congenital heart disease undergoing cardiac surgery with cardiopulmonary bypass].
Paśnik J; Cywińska-Bernas A; Moll J; Moll J; Sysa A; Zeman K
Przegl Lek; 2009; 66(7):359-64. PubMed ID: 20043576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
